Boston Scientific Gestione
Gestione criteri di controllo 3/4
Boston Scientific Il CEO è Mike Mahoney, nominato in Oct2011, e ha un mandato di 13.08 anni. la retribuzione annua totale è $ 18.72M, composta da 7.5% di stipendio e 92.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di $ 156.52M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.6 anni e 8.3 anni.
Informazioni chiave
Mike Mahoney
Amministratore delegato
US$18.7m
Compenso totale
| Percentuale dello stipendio del CEO | 7.5% |
| Mandato del CEO | 13.1yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 8.6yrs |
| Durata media del Consiglio di amministrazione | 8.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$19m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$861m |
| Mar 31 2023 | n/a | n/a | US$846m |
| Dec 31 2022 | US$17m | US$1m | US$642m |
| Sep 30 2022 | n/a | n/a | US$596m |
| Jun 30 2022 | n/a | n/a | US$828m |
| Mar 31 2022 | n/a | n/a | US$754m |
| Dec 31 2021 | US$16m | US$1m | US$985m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$526m |
| Mar 31 2021 | n/a | n/a | US$201m |
| Dec 31 2020 | US$14m | US$667k | -US$115m |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$4b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$16m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$14m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$670m |
| Jun 30 2018 | n/a | n/a | US$521m |
| Mar 31 2018 | n/a | n/a | US$112m |
| Dec 31 2017 | US$13m | US$1m | US$104m |
Compensazione vs Mercato: La retribuzione totale di Mike ($USD 18.72M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 12.74M ).
Compensazione vs guadagni: La retribuzione di Mike è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Mike Mahoney (59 yo)
13.1yrs
Mandato
US$18,723,735
Compensazione
Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 13.1yrs | US$18.72m | 0.12% $ 156.5m | |
| Executive VP & CFO | 10.8yrs | US$5.83m | 0.015% $ 20.2m | |
| Executive VP & Group President of Cardiology | 14.8yrs | US$5.59m | 0.011% $ 15.0m | |
| Executive VP & President of Peripheral Interventions | 11.8yrs | US$3.78m | 0.0019% $ 2.5m | |
| Executive VP and Group President of MedSurg & Asia Pacific | 8.3yrs | US$4.27m | 0.0016% $ 2.2m | |
| Executive Vice President of Global Operations | 2.5yrs | Nessun dato | 0.0025% $ 3.4m | |
| Senior VP | less than a year | Nessun dato | 0.00026% $ 346.6k | |
| Senior VP and Chief Information & Digital Officer | 8.9yrs | Nessun dato | Nessun dato | |
| Senior VP of Investor Relations | less than a year | Nessun dato | 0.0026% $ 3.4m | |
| Senior VP | 3.4yrs | Nessun dato | 0.0023% $ 3.1m | |
| Senior VP of Market Access & Chief Marketing Officer | 3.5yrs | Nessun dato | Nessun dato | |
| Executive Vice President of Human Resources | 11.9yrs | Nessun dato | 0.0022% $ 2.9m |
8.6yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di BSX è esperto e expertise (durata media dell'incarico 8.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 12yrs | US$18.72m | 0.12% $ 156.5m | |
| Lead Independent Director | 10.7yrs | US$360.00k | 0.0030% $ 4.0m | |
| Independent Director | 8.6yrs | US$335.00k | 0.0033% $ 4.4m | |
| Independent Director | 8.3yrs | US$320.00k | 0.00020% $ 266.6k | |
| Independent Director | 3.4yrs | US$338.75k | 0.0027% $ 3.6m | |
| Director | less than a year | Nessun dato | Nessun dato | |
| Director | less than a year | Nessun dato | 0.00024% $ 319.9k | |
| Independent Director | 9.6yrs | US$326.25k | 0.0043% $ 5.7m | |
| Independent Director | 15.6yrs | US$340.00k | 0.0036% $ 4.8m | |
| Independent Director | 1.4yrs | US$233.23k | 0.00042% $ 559.9k | |
| Independent Director | 1.4yrs | US$233.23k | 0.00027% $ 359.9k |
8.3yrs
Durata media
60.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BSX sono considerati esperti (durata media dell'incarico 8.3 anni).